| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | John Mendelsohn | |
| P433 | issue | 18 Suppl | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1S-13S | |
| P577 | publication date | 2002-09-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Targeting the epidermal growth factor receptor for cancer therapy | |
| P478 | volume | 20 |
| Q28543105 | A computational strategy to select optimized protein targets for drug development toward the control of cancer diseases |
| Q38603140 | A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839) |
| Q42958057 | ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab—Clinical Implications in Colorectal Cancer |
| Q37781665 | Angiogenesis as a therapeutic target in urothelial carcinoma |
| Q55140322 | Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis. |
| Q52633490 | Anti-epidermal growth factor receptor therapy concurrently with induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. |
| Q36321184 | Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer |
| Q39865068 | Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo |
| Q34792693 | Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. |
| Q39911160 | Aptamers selected against the unglycosylated EGFRvIII ectodomain and delivered intracellularly reduce membrane-bound EGFRvIII and induce apoptosis |
| Q35842099 | Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling |
| Q33433688 | Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis |
| Q35200393 | Cetuximab in non-small-cell lung cancer |
| Q36989648 | Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced non-small cell lung cancer |
| Q37155553 | Chemotherapy for metastatic gastric cancer: past, present, and future |
| Q37181068 | Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers |
| Q34031281 | Clinical and scientific impact of human papillomavirus on head and neck cancer |
| Q36045952 | Clinical experience with monoclonal antibodies to epidermal growth factor receptor |
| Q27851527 | Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones |
| Q40109785 | Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up |
| Q34721253 | Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks. |
| Q34252140 | Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC. |
| Q37123936 | Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients w |
| Q37184167 | Current aspects of targeted therapy in head and neck tumors |
| Q54450580 | Cyclin D1, EGFR, and Akt/mTOR pathway. Potential prognostic markers in localized laryngeal squamous cell carcinoma. |
| Q39747000 | Development of chimeric gene regulators for cancer-specific gene therapy with both transcriptional and translational targeting |
| Q28477182 | Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer |
| Q36489873 | EGF receptors as a target for cancer therapy |
| Q37205334 | EGFR and KRAS mutations in patients with adenocarcinoma of the lung |
| Q38072670 | EGFR-directed monoclonal antibodies in non-small cell lung cancer |
| Q35200322 | EGFR-directed monoclonal antibodies in non-small cell lung cancer: how to predict efficacy? |
| Q40740471 | Efficacy of Cetuximab in Combination with Chemotherapy in Advanced Non-small Cell Lung Cancer |
| Q36616502 | Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR |
| Q33869583 | Enhanced expression of epidermal growth factor receptor gene in gastric mucosal cells by the serum derived from rats treated with electroacupuncture at stomach meridian acupoints |
| Q33693476 | Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR. |
| Q40448827 | Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors. |
| Q73470620 | Epidermal growth factor receptor is a marker for syncytiotrophoblastic cells in testicular germ cell tumors |
| Q33996096 | Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib |
| Q40018113 | Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. |
| Q55317834 | Expression of p53 & epidermal growth factor receptor in glioblastoma. |
| Q35886688 | HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK. |
| Q36117785 | Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma |
| Q39842379 | Impact of erythropoietin on the effects of irradiation under hypoxia. |
| Q38936986 | In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells |
| Q37141676 | Incorporation of biologic therapies in the management of gastroesophageal cancers |
| Q36806950 | Inhibition of TGF-β enhances the in vivo antitumor efficacy of EGF receptor-targeted therapy |
| Q34751465 | Intracellular trafficking considerations in the development of natural ligand-drug molecular conjugates for cancer |
| Q51701640 | KRAS testing and its importance in colorectal cancer. |
| Q35753530 | Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction |
| Q37341649 | Lapatinib - overview and current role in metastatic breast cancer |
| Q41907024 | Metastatic gastric cancer - focus on targeted therapies |
| Q48451660 | Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. |
| Q34326593 | Molecular targeting to treat gastric cancer |
| Q34625408 | Monoclonal antibodies against EGFR in non-small cell lung cancer |
| Q37256737 | NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells. |
| Q39431960 | Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways |
| Q41033340 | Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities |
| Q35882193 | Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression |
| Q36116250 | Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy |
| Q35911350 | Personalized therapy in endometrial cancer: challenges and opportunities |
| Q33990908 | Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. |
| Q37401491 | Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). |
| Q33378256 | Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study |
| Q36717778 | Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer |
| Q35905876 | Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling |
| Q38873993 | Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles |
| Q39706629 | Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein |
| Q37771250 | Rational use of cetuximab in the treatment of advanced non-small cell lung cancer. |
| Q41170260 | Reduction of G0 phase cells of colon cancer caco-2 cells may enhance 5-fluorouracil efficacy |
| Q28242840 | Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy |
| Q37468539 | Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies |
| Q36803657 | Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro |
| Q35220347 | Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites |
| Q37582080 | Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033. |
| Q36146089 | Synergistic Inhibitory Effects of Cetuximab and Cisplatin on Human Colon Cancer Cell Growth via Inhibition of the ERK-Dependent EGF Receptor Signaling Pathway |
| Q38992642 | Synthesis, molecular docking and biological evaluation of glycyrrhizin analogs as anticancer agents targeting EGFR. |
| Q42365964 | Targeted nanoparticles for colorectal cancer. |
| Q37290448 | Targeted therapies in the management of metastatic bladder cancer |
| Q37500197 | Targeting Anti-Cancer Active Compounds: Affinity-Based Chromatographic Assays. |
| Q83593112 | Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab |
| Q37290648 | Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab. |
| Q35828552 | Targeting the epidermal growth factor receptor |
| Q36689474 | The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy |
| Q36983954 | The problem of cancer dormancy: understanding the basic mechanisms and identifying therapeutic opportunities. |
| Q36536674 | The role of pharmacogenetics in cancer therapeutics |
| Q37362948 | Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience |
| Q33304557 | Why do cancer cells become "addicted" to oncogenic epidermal growth factor receptor? |
| Q80098830 | [Designer-drugs in tumor treatment] |
| Q83298961 | [Human papillomavirus and cancer of the oropharynx. Molecular interaction and clinical implications] |
| Q53379524 | [Perspectives for molecular diagnostics exemplified by urothelial bladder carcinoma]. |
Search more.